Regulators from EU, U.S. and Japan join forces on antimicrobial trials

Destiny Pharma is pleased to note that the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the United States’ Food and Drug Administration (FDA) have agreed to align their data requirements for antimicrobial trials, aimed at stimulating the development of new treatments to fight antimicrobial resistance. More information is available on the EMA website.